PS
CRSP icon

PayPay Securities’s CRISPR Therapeutics CRSP Stock Holding History

PayPay Securities’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$818 Sell
15
-5
-25% -$264 0.02% 279
2026
Q1 		$1.11K Sell
20
-2
-9% -$105 0.04% 226
2025
Q4 		$1.15K Buy
22
+6
+38% +$359 0.03% 243
2025
Q3 		$1.03K Buy
16
+2
+14% +$115 0.04% 220
2025
Q2 		$681 Sell
14
-3
-18% -$116 0.03% 231
2025
Q1 		$605 Sell
17
-8
-32% -$339 0.03% 244
2024
Q4 		$984 Buy
25
+19
+317% +$897 0.04% 216
2024
Q3 		$282 Sell
6
-5
-45% -$254 0.03% 178
2024
Q2 		$594 Sell
11
-7
-39% -$405 0.05% 174
2024
Q1 		$1.23K Sell
18
-3
-14% -$215 0.06% 177
2023
Q4 		$1.32K Buy
21
+5
+31% +$276 0.06% 178
2023
Q3 		$6.04K Buy
16
+1
+7% +$52 0.28% 87
2023
Q2 		$842 Sell
15
-3
-17% -$170 0.05% 157
2023
Q1 		$814 Sell
18
-27
-60% -$1.31K 0.05% 166
2022
Q4 		$1.83K Buy
+45
New +$2.39K 0.12% 140

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

PayPay Securities's CRSP Position: Q2 2026 in Review

PayPay Securities reduced its CRISPR Therapeutics (CRSP) stake by 25% in Q2 2026, selling an estimated $264 and leaving 15 shares worth $818. The position accounts for 0.02% of the portfolio, ranked #279.

PayPay Securities first reported a position in CRSP in Q4 2022 and has held it in 15 quarters since. The position peaked at $6.04K in Q3 2023. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • PayPay Securities held 15 shares of CRISPR Therapeutics worth $818 as of Q2 2026.
  • PayPay Securities sold 5 CRISPR Therapeutics shares in Q2 2026, an estimated $264.
  • CRISPR Therapeutics made up 0.02% of PayPay Securities's portfolio in Q2 2026, its #279 holding.
  • PayPay Securities first reported a position in CRISPR Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • PayPay Securities's CRISPR Therapeutics position peaked at $6.04K in Q3 2023.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on PayPay Securities's 13F filing for Q2 2026, filed 23 Jul 2026.